- Cosmetic Peptides
- Peptides APIs
- Catalog Peptides
- Cosmetic Ingredients
- Amino Acid & Vitamin
- Edible Gum
- Nutrition Supplements
- Plant Extracts
- Packaging Equipments
Cheap Pharmaceutical Peptide Sandostatin Octreotide Acetate CAS 83150-76-9 Quality GuaranteeChat Now
Cheap Pharmaceutical Peptide Sandostatin Octreotide Acetate CAS 83150-76-9 Quality Guarantee
Base information of Octreotide Acetate
Chemical Name:Octreotide Acetate
Cas No: 83150-76-9
Sequence:D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-L-cysteinamide Cyclic (2-7)-Disulfide Acetate
Also known as: Sandostatin, Sandostatine, SAN 201995,Compound 201 995,Sandostatine, Octreotide Acetate Salt, Sandoz 201-995, Octreotidum, Octreotida, DRG-0115
Appearance: white powder
Quality: As described on COA/MS/HPLC/MSDS reports
Sample orders: 2 Grams
Delivery: Within 3-5 days
Shipping: By Express DHL/TNT with tracking number provided
Descriptions of Octreotide Acetate
Octreotide is an octapeptide that mimics natural somatostatin pharmacologically, though it is a more potent inhibitor of growth hormone,glucagon, and insulin than the natural hormone. It was first synthesized in 1979 by the chemist Wilfried Bauer.
Need long-term Mr Qu peptide treatment of acromegaly, activity, such as postoperative residual tumor growth hormone to increase serum levels of growth hormone, pituitary after external beam radiotherapy has yet to reach full therapeutic serum growth hormone levels, some are not suitable for the surgical treatment and new diagnosis of growth hormone secretion adenomas in patients with preoperative treatment.
Sample pictures of Octreotide Acetate
Quality Reports of Octreotide Acetate
Research of Octreotide Acetate
Octreotide has also been used off-label for the treatment of severe, refractory diarrhea from other causes. It is used in toxicology for the treatment of prolonged recurrent hypoglycemia after sulfonylurea and possibly meglitinides overdose. It has also been used with varying degrees of success in infants with nesidioblastosis to help decrease insulin hypersecretion.
Octreotide has been used experimentally to treat obesity, particularly obesity caused by lesions in the hunger and satiety centers of the hypothalamus, a region of the brain central to the regulation of food intake and energy expenditure. The circuit begins with an area of the hypothalamus, the arcuate nucleus, that has outputs to the lateral hypothalamus (LH) and ventromedial hypothalamus (VMH), the brain's feeding and satiety centers, respectively. The VMH is sometimes injured by ongoing treatment for acute lymphoblastic leukemia (ALL) or surgery or radiation to treat posterior cranial fossa tumors.
Remarks: The product is non-medicine,forbidden for private consume directly.